Ad26 Mos4 HIV vaccine - Janssen Vaccines and Prevention

Drug Profile

Ad26 Mos4 HIV vaccine - Janssen Vaccines and Prevention

Alternative Names: Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos4.HIV; Adenovirus serotype-26 mosaic-4 HIV vaccine; Adenovirus serotype-26 mosaic-4 human immunodeficiency virus vaccine; Tetravalent Ad26 Mos HIV

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Crucell Holland
  • Developer Janssen Vaccines and Prevention B.V
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 01 Mar 2017 Janssen Vaccines & Prevention B.V plans a phase II trial for HIV infections (Prevention) in South Africa (NCT03060629)
  • 14 Oct 2016 Janssen Vaccines & Prevention B.V. plans the phase I/IIa IPCAVD-012 trial for HIV infections (Prevention) in USA, Kenya and Rwanda (IM) (NCT02935686)
  • 01 Jul 2016 Phase-II clinical trials in HIV infections (Prevention) in USA (IM) (NCT02788045)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top